Nevertheless, BRAF/MEK inhibitor combinations are now accepted as the standard of care for BRAF-mutant advanced melanoma and the trametinib/dabrafenib and cobimetinib/vemurafenib combinations received FDA approval in 2014 and 2015, respectively. The gene discussed is MAP2K7; the disease is melanoma.